Flow cytometry was performed to confirm the MS results on several critical markers of tumor immune responses including CD25 (IL2RA), CD5, CD137 (TNFRSF9), ICOS, PD1 (PDCD1), CTLA4, and CD62L (SELL) (Fig. 4e–g). The gene discussed is SELL; the disease is neoplasm.